Literature DB >> 27143255

Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.

Kazuhiro Mochizuki1, Lijun Meng2, Izumi Mochizuki1, Qing Tong3, Shan He3, Yongnian Liu3, Janaki Purushe4, Henry Fung5, M Raza Zaidi3, Yanyun Zhang6, Ran Reshef7, Bruce R Blazar8, Hideo Yagita9, Shin Mineishi10, Yi Zhang11.   

Abstract

Alloreactive T cells play a critical role in eliminating hematopoietic malignant cells but are also the mediators of graft-versus-host disease (GVHD), a major complication that subverts the success of allogeneic hematopoietic stem cell transplantation (HSCT). However, induction of alloreactive T cells does not necessarily lead to GVHD. Here we report the development of a cellular programming approach to render alloreactive T cells incapable of causing severe GVHD in both major histocompatibility complex (MHC)-mismatched and MHC-identical but minor histocompatibility antigen-mismatched mouse models. We established a novel platform that produced δ-like ligand 4-positive dendritic cells (Dll4(hi)DCs) from murine bone marrow using Flt3 ligand and Toll-like receptor agonists. Upon allogeneic Dll4(hi)DC stimulation, CD4(+) naïve T cells underwent effector differentiation and produced high levels of interferon γ (IFN-γ) and interleukin-17 in vitro, depending on Dll4 activation of Notch signaling. Following transfer, allogeneic Dll4(hi)DC-induced T cells were unable to mediate severe GVHD but preserved antileukemic activity, significantly improving the survival of leukemic mice undergoing allogeneic HSCT. This effect of Dll4(hi)DC-induced T cells was associated with their impaired expansion in GVHD target tissues. IFN-γ was important for Dll4(hi)DC programming to reduce GVHD toxicities of alloreactive T cells. Absence of T-cell IFN-γ led to improved survival and expansion of Dll4(hi)DC-induced CD4(+) T cells in transplant recipients and caused lethal GVHD. Our findings demonstrate that Dll4(hi)DC programming can overcome GVHD toxicity of donor T cells and produce leukemia-reactive T cells for effective immunotherapy.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27143255      PMCID: PMC4920025          DOI: 10.1182/blood-2015-05-644476

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  58 in total

1.  IL-2 secretion and T cell clonal anergy are induced by distinct biochemical pathways.

Authors:  S D Norton; D E Hovinen; M K Jenkins
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

2.  A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells.

Authors:  Kathryn W Juchem; Britt E Anderson; Cuiling Zhang; Jennifer M McNiff; Anthony J Demetris; Donna L Farber; Andrew J Caton; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

Review 3.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

4.  Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ.

Authors:  Britt E Anderson; Jennifer M McNiff; Dhanpat Jain; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2004-11-02       Impact factor: 22.113

Review 5.  Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

6.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

7.  IL-17 contributes to CD4-mediated graft-versus-host disease.

Authors:  Lucy W Kappel; Gabrielle L Goldberg; Christopher G King; David Y Suh; Odette M Smith; Cassandra Ligh; Amanda M Holland; Jeremy Grubin; Nicholas M Mark; Chen Liu; Yoichiro Iwakura; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

8.  Mastermind critically regulates Notch-mediated lymphoid cell fate decisions.

Authors:  Ivan Maillard; Andrew P Weng; Andrea C Carpenter; Carlos G Rodriguez; Hong Sai; Lanwei Xu; David Allman; Jon C Aster; Warren S Pear
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

Review 9.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

10.  Notch signaling is an important regulator of type 2 immunity.

Authors:  Lili Tu; Terry C Fang; David Artis; Olga Shestova; Seth E Pross; Ivan Maillard; Warren S Pear
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

View more
  13 in total

Review 1.  DLL4+ dendritic cells: Key regulators of Notch Signaling in effector T cell responses.

Authors:  Lijun Meng; Shaoyan Hu; Jian Wang; Shan He; Yi Zhang
Journal:  Pharmacol Res       Date:  2016-09-14       Impact factor: 7.658

Review 2.  Epigenetic Regulation of Dendritic Cell Development and Function.

Authors:  Yuanyuan Tian; Lijun Meng; Yi Zhang
Journal:  Cancer J       Date:  2017 Sep/Oct       Impact factor: 3.360

3.  Notch Signaling and Immune Regulation in Alloimmunity.

Authors:  Naoka Murakami; Ivan Maillard; Leonardo V Riella
Journal:  Curr Transplant Rep       Date:  2016-10-10

4.  Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction.

Authors:  Yuanyuan Tian; Lijun Meng; Ying Wang; Bohan Li; Hongshuang Yu; Yan Zhou; Tien Bui; Ciril Abraham; Alicia Li; Yongping Zhang; Jian Wang; Chenchen Zhao; Shin Mineishi; Stefania Gallucci; David Porter; Elizabeth Hexner; Hong Zheng; Yanyun Zhang; Shaoyan Hu; Yi Zhang
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

5.  AAV-Vectored Fms-Related Tyrosine Kinase 3 Ligand Inhibits CD34+ Progenitor Cell Engraftment in Humanized Mice.

Authors:  Lijun Ling; Xian Tang; Xiuyan Huang; Jingjing Li; Hui Wang; Zhiwei Chen
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-30       Impact factor: 4.147

Review 6.  A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.

Authors:  Erhao Zhang; Hanmei Xu
Journal:  J Hematol Oncol       Date:  2017-01-03       Impact factor: 17.388

7.  Bone marrow transplant-induced alterations in Notch signaling promote pathologic Th17 responses to γ-herpesvirus infection.

Authors:  S J Gurczynski; X Zhou; M Flaherty; C A Wilke; B B Moore
Journal:  Mucosal Immunol       Date:  2017-10-18       Impact factor: 7.313

Review 8.  Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance.

Authors:  Hongshuang Yu; Yuanyuan Tian; Ying Wang; Shin Mineishi; Yi Zhang
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

Review 9.  Current Views on the Roles of O-Glycosylation in Controlling Notch-Ligand Interactions.

Authors:  Wataru Saiki; Chenyu Ma; Tetsuya Okajima; Hideyuki Takeuchi
Journal:  Biomolecules       Date:  2021-02-18

10.  Child with Wiskott-Aldrich syndrome underwent atypical immune reconstruction after umbilical cord blood transplantation: A case report.

Authors:  Bo-Han Li; Shao-Yan Hu
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.